Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to dissemintate knowledge & skills of Acute Cardiovascular Care
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission: To promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our goal is to reduce the burden in cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our Mission is "to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death"
To improve quality of life and logevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
Working Groups goals is to stimulate and disseminate scientific knowledge in different fields of cardiology.
ESC Councils goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Dr. Borge Nordestgaard
Borge Nordestgaard (Denmark)
List of Authors: Birgitte Fischer Sode, Morten Dahl, Børge G Nordestgaard
Aim: Myocardial infarction is nominally the most important co-morbidity in patients with chronic obstructive pulmonary disease (COPD), and the one with the greatest potential for treatment and prevention to improve the overall prognosis of COPD patients. We assessed the extent of myocardial infarction and other co-morbidities in individuals with COPD in the general population. Methods & results: We used individual participant data for the entire Danish population from 1980 through 2006, comprising 140 million person-years of follow-up. We used information from four national Danish registries with 100% follow-up and detected ever diagnosed COPD (n=313,958) and incident cases of a first myocardial infarction (n=422,344), lung cancer (n=115,296), hip fracture (n=53,756), depression (n=91,868), and diabetes mellitus (n=290,942). Multivariate adjusted hazard ratios for life-time association with ever-diagnosed COPD were 1.26 (95% CI 1.25-1.27) for myocardial infarction, 2.05 (2.03-2.08) for lung cancer, 2.12 (2.07-2.17) for hip fracture, 1.74 (1.70-1.77) for depression, and 1.21 (1.20-1.23) for diabetes mellitus, compared with controls; these risk estimates were highest in women and the youngest age groups. Before the first hospitalisation with COPD, multivariate adjusted odds ratios were 1.47 (1.44-1.49) for myocardial infarction, 3.68 (3.52-3.84) for lung cancer, 1.16 (1.13-1.18) for hip fracture, 1.88 (1.80-1.96) for depression, and 1.16 (1.13-1.18) for diabetes mellitus, compared with matched controls. Corresponding values after a COPD hospitalisation were 0.74 (0.73-0.76), 1.48 (1.45-1.51), 1.23 (1.20-1.27), 1.21 (1.18-1.24), and 0.83 (0.81-0.85), respectively. Conclusion: COPD was associated with higher rates of myocardial infarction, lung cancer, diabetes, hip fracture, and depression, but the strength of these associations were modified after a first admission for COPD. These associations may be related to common genetic and/or lifestyle/environmental risk factors, and therefore these factors are likely to have an adverse health impact rather than COPD per se.
Clinical Registry Highlight II - Interventions and devices